Oryzon Genomics S.A. (ORY.MC)
Develops experimental drugs targeting epigenetics to treat cancer and neurological diseases.
2.90-0.02%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+11.1%
The outlook
Oryzon Genomics trades at €2.90, positioned low within its 52-week range and below both short and long-term moving averages. Analysts are unanimously bullish with a Strong Buy consensus, and their average price target sits roughly 146% above the current price. The stock's overall momentum appears subdued despite the positive analyst view.
What’s behind the score
Analyst consensusStrong Buy — 1.0 avg of 3 analysts
Price trendBelow its 50- & 200-day averages
52-week range24% of the way from its 52-week low to high
Price targetAvg target +146% vs current price
Analyst price target
~12-month · 3 analysts7.13average target+146.0% vs now
Now 2.90
Low 4.20High 12.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$237.7M
52-wk high
4.02
52-wk low
2.56
50-day avg
3.03
200-day avg
3.05
Trailing P/E
—